Antidepressants and Sexual Side Effects

Depends entirely on who asks

Measured properly, with direct questioning or a validated questionnaire, treatment-emergent sexual dysfunction runs from about twenty-six to eighty per cent depending on the drug. In a study of 1,022 outpatients, the overall figure was fifty-nine per cent, and for SSRIs and venlafaxine specifically the range was fifty-eight to seventy-three per cent.

The single most useful number is the detection gap. In a study of 344 patients, sexual dysfunction was reported spontaneously by fourteen per cent and found in fifty-eight per cent when the physician asked. That gap has not closed: in a 2025 study of 452 outpatients, only around a third of women and two-fifths of men volunteered the problem.

This is why database studies produce figures orders of magnitude lower. They count only what reaches medical attention, and most of this never does.

The choice genuinely changes the odds

This is the most actionable part of the page. Rates differ several-fold between antidepressants.

In meta-analysis, rates were significantly higher than placebo for sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, duloxetine, escitalopram and fluvoxamine, and not significantly different from placebo for bupropion, mirtazapine, agomelatine and moclobemide. Note carefully that not significantly different from placebo is a statistical statement, not a promise: mirtazapine’s raw rate is around a quarter, which is not zero.

Indian data show the same pattern at somewhat lower absolute rates. A naturalistic Indian comparison found sexual dysfunction in about sixty-one per cent on escitalopram, thirty-six per cent on desvenlafaxine and twenty-five per cent on mirtazapine. Agomelatine, one of the lower-risk options, is marketed in India.

More than one thing

Framing this as an erection problem causes women’s difficulties and most men’s to go unrecognised. Desire, arousal, lubrication, erection, orgasm and ejaculation delay, and overall satisfaction are all affected. Men have a slightly higher overall incidence; women report greater severity.

Against placebo, the most recent meta-analysis found SSRIs roughly tripled the risk of orgasmic dysfunction, modestly reduced sexual satisfaction, and did not significantly change desire.

Genital numbness deserves separate mention, because the standard questionnaires do not ask about it. If it is happening, it will not appear in a routine assessment unless you say so.

Which is why the question has to come first

Depression itself substantially impairs sexual function, and any honest discussion has to include this. In people with major depression who were taking no medication at all, sexual dysfunction was found in about eighty-three per cent of women and sixty-three per cent of men.

This is not an argument for dismissing the drug effect, which is real and measurable on top. It is the strongest argument there is for asking before prescribing. Without a baseline, the question of whether it is the illness or the tablet cannot be answered afterwards, and both patient and doctor are left guessing.

Our article on whether erectile difficulty is psychological or medical covers the non-medication side of that question.

Options, ranked by how well they are evidenced

The Cochrane review of twenty-three randomised trials covering 1,886 participants is the reference point, and its own verdict is that the available evidence is rather limited. Within that limit:

Waiting it out is the weakest option. In the largest prospective study, only about six per cent had complete resolution within six months of continuing, while eighty-one per cent showed no improvement at all. A few weeks of watching is reasonable. Six months of waiting is not a plan.

Drug holidays, meaning planned days off the medicine, have some newer supportive evidence in women but carry real problems: withdrawal symptoms, relapse risk, and the behavioural difficulty of teaching someone that skipping doses is acceptable. They are also pharmacologically meaningless with fluoxetine.

What regulators have actually concluded

Some people report sexual difficulties that continue after the antidepressant has been stopped. This is usually called post-SSRI sexual dysfunction, or PSSD, and it deserves a straight answer rather than either dismissal or alarm.

In May 2019 the European Medicines Agency’s safety committee required a label change for SSRIs and SNRIs, adding wording that there have been reports of long-lasting sexual dysfunction where symptoms continued despite stopping treatment. That is a real regulatory action based on reported cases and published literature.

What regulators did not do is establish a frequency or a mechanism. The only population-database estimate, from nineteen years of Israeli health data, put the risk at roughly one in 216 patients, and its own authors note that it used erectile-dysfunction prescriptions as a proxy and probably underestimates. Self-selected surveys of former users report far higher figures, but those cannot be read as prevalence.

The defensible position is this: sexual side effects during treatment are common, dose-related and usually reversible. A persistent syndrome after stopping is recognised by regulators, real for the people who have it, and rare enough that no reliable frequency has been established. Anyone telling you confidently that it is common, or that it never happens, is going beyond the evidence.

Where the conversation tends not to happen

Every reason for under-disclosure is amplified here: short consultations, family members present in the room, and strong reticence about sexual matters. Indian studies find lower reported rates than Western questionnaire-based studies, and it would be a mistake to read that as a real biological difference.

There is a further complication specific to this region. Where beliefs about sexual weakness and semen loss are common, a genuine medication side effect may be attributed to something else entirely, and the person may seek help outside medicine rather than mentioning it at the next review. The relevant Indian study found that antidepressant-associated sexual dysfunction was significantly associated with poorer quality of life and poorer marital adjustment, so this is not a minor matter.

One practical warning. Sildenafil and tadalafil are prescription medicines in India, and Indian regulators have recently acted against unauthorised sale and promotion of sexual enhancement medicines, citing counterfeits with wrong doses or harmful ingredients. The same drug that the trial evidence supports can be prescribed properly and safely, which makes buying it from an unregulated source both risky and unnecessary.

A sentence that is enough

You do not need a vocabulary for this. Something as plain as "since starting this tablet, sex has changed and I want to talk about it" is a complete opening, and any psychiatrist will take it from there.

It is worth doing, because the alternative is worse. A national medicines regulator describes sexual dysfunction as the most common reason patients stop antidepressants and antipsychotics, frequently without informing the prescriber. Stopping abruptly risks both withdrawal symptoms and relapse, and there are usually several better options that were never discussed.